

# EURICAN DAPPI LYOPHILISATE AND SOLVENT FOR SUSPENSION FOR INJECTION

Authorised

- Canine parainfluenza virus, strain CGF 2004/75, Live
- Canine distemper virus, strain BA5, Live
- Canine parvovirus, strain CAG2, Live
- Canine adenovirus 2, strain DK13, Live

## Product identification

**Medicine name:**

EURICAN DAPPI LYOPHILISATE AND SOLVENT FOR SUSPENSION FOR INJECTION

---

**Active substance:**

Canine parainfluenza virus, strain CGF 2004/75, Live

Canine distemper virus, strain BA5, Live

Canine parvovirus, strain CAG2, Live

Canine adenovirus 2, strain DK13, Live

---

**Target species:**

Dog

---

**Route of administration:**

Subcutaneous use

---

## Product details

### **Active substance and strength:**

Canine parainfluenza virus, strain CGF 2004/75, Live  
4.70 log<sub>10</sub> 50% cell culture infectious dose / 1.00 Dose

Canine distemper virus, strain BA5, Live  
4.00 log<sub>10</sub> 50% cell culture infectious dose / 1.00 Dose

Canine parvovirus, strain CAG2, Live  
4.90 log<sub>10</sub> 50% cell culture infectious dose / 1.00 Dose

Canine adenovirus 2, strain DK13, Live  
2.50 log<sub>10</sub> 50% cell culture infectious dose / 1.00 Dose

---

### **Pharmaceutical form:**

Lyophilisate and solvent for suspension for injection

---

### **Anatomical therapeutic chemical veterinary (ATCvet) codes:**

QI07AD04

---

### **Legal status of supply:**

Veterinary medicinal product subject to veterinary prescription

---

### **Authorisation status:**

Valid

---

### **Authorised in:**

Slovakia

---

### **Package description:**

Plastic box of 10 vials of lyophilisate (1 dose)

Plastic box of 50 vials of lyophilisate (1 dose)

Plastic box of 100 vials of lyophilisate (1 dose)

Plastic box of 10 vials of solvent (1 ml)

Plastic box of 50 vials of solvent (1 ml)

Plastic box of 100 vials of solvent (1 ml)

Plastic box of 10 vials of lyophilisate (1 dose) and 10 vials of solvent (1 ml)

Plastic box of 100 vials of lyophilisate (1 dose) and 100 vials of solvent (1 ml)

Plastic box of 50 vials of lyophilisate (1 dose) and 50 vials of solvent (1 ml)

---

## Additional information

**Entitlement type:**

Marketing Authorisation

---

**Legal basis of product authorisation:**

Full application - Known active substance (Article 12(3) of Directive No 2001/82/EC)

---

**Marketing authorisation holder:**

Boehringer Ingelheim Animal Health France

---

**Marketing authorisation date:**

26/04/2017

---

**Manufacturing sites for batch release:**

Boehringer Ingelheim Animal Health France

---

**Responsible authority:**

Institute For State Control Of Veterinary Biologicals And Medicaments

---

**Authorisation number:**

97/016/MR/17-S

---

**Date of authorisation status change:**

26/04/2017

---

**Reference member state:**

France

---

**Procedure number:**

FR/V/0306/001

---

**Concerned member states:**

Austria Belgium Bulgaria Croatia Cyprus Czechia Denmark Estonia Finland  
Germany Greece Hungary Ireland Italy Latvia Lithuania Luxembourg Malta  
Netherlands Norway Poland Portugal Romania Slovakia Slovenia Spain  
Sweden United Kingdom (Northern Ireland)

---

To consult adverse reactions on veterinary medicinal products please go to [www.adrreports.eu/vet](http://www.adrreports.eu/vet)

## Documents

Combined File of all Documents

This document does not exist in this language (English). You can find it in another language below.